Entrada reports ~$420M cash; DMD pipeline advancing with multiple 2025 trial starts

Entrada Therapeutics, Inc.

Preliminary cash resources ~$420M as of Dec 31, 2024, extending runway into Q2 2027.
Phase 1 ENTR-601-44 data: no treatment-related AEs; dose-dependent PK/PD and statistically significant exon skipping at 6 mg/kg.
Plans to initiate Phase 1/2 MAD studies for ENTR-601-44, -45, -50, and -51 in 2025; Vertex advancing VX-670 MAD portion in DM1.
Preclinical data show dose-dependent dystrophin restoration and functional correction in DMD mouse models across franchise.
Cash and clinical updates based on preliminary unaudited estimates; year-end audit ongoing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.